Literature DB >> 26843057

Characteristics of second breast events among women treated with breast-conserving surgery for DCIS in the community.

Michael J Hassett1,2, Wei Jiang3, Laurel A Habel4, Larissa Nekhlyudov5,6, Ninah Achacoso7, Luana Acton8, Stuart J Schnitt9, Deb Schrag10,11, Rinaa S Punglia12,13.   

Abstract

We examined the clinical/pathologic features of ipsilateral second breast cancers (IP-SBCs) following breast-conserving surgery (BCS) for DCIS among community-treated patients and ascertained the degree of correlation between the features of index DCIS and IP-SBC events. From a Cancer Research Network cohort of DCIS patients diagnosed 1990-2001 and treated with BCS, we identified women who subsequently developed an ipsilateral DCIS or invasive breast cancer. All index DCIS tumors underwent expert pathology review. Pathologic characteristics of IP-SBCs were abstracted from available medical records. Logistic regression was used to examine associations between pathologic characteristics and identify factors associated with invasive versus non-invasive IP-SBC. Of 1969 DCIS patients, 182 developed an IP-SBC within a median of 38 months (range 6-160). IP-SBCs were slightly more commonly non-invasive (53 %) versus invasive (47 %). Of invasive IP-SBCs, 31 % were high grade, 67 % were <20 mm, 74 % were estrogen receptor positive, 7 % were HER2 positive, and 16 % were node positive. Of non-invasive IP-SBCs, 33 % were high grade. Comparing index DCIS and IP-SBC specimens, there was moderate-high correlation for HR status and grade. Among patients with IP-SBCs, those who were younger and whose index DCIS tumors were HR negative had shorter intervals (within 3 years) between index and IP-SBC diagnoses. No index DCIS feature was statistically significantly associated with an IP-SBC that was invasive versus non-invasive. Understanding the characteristics of SBCs and identifying correlations between these and index DCIS events could influence treatment choices for DCIS, and may help patients and providers develop treatment paradigms for SBCs.

Entities:  

Keywords:  Breast cancer; DCIS; Grade; Hormone receptor; Recurrence; Second breast cancer

Mesh:

Year:  2016        PMID: 26843057      PMCID: PMC4767622          DOI: 10.1007/s10549-016-3692-4

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  32 in total

1.  Detection of ductal carcinoma in situ in women undergoing screening mammography.

Authors:  Virginia L Ernster; Rachel Ballard-Barbash; William E Barlow; Yingye Zheng; Donald L Weaver; Gary Cutter; Bonnie C Yankaskas; Robert Rosenberg; Patricia A Carney; Karla Kerlikowske; Stephen H Taplin; Nicole Urban; Berta M Geller
Journal:  J Natl Cancer Inst       Date:  2002-10-16       Impact factor: 13.506

2.  Nonpalpable invasive breast cancer.

Authors:  M C Wilhelm; S B Edge; D D Cole; E deParedes; H F Frierson
Journal:  Ann Surg       Date:  1991-06       Impact factor: 12.969

3.  Fifteen-year results of breast-conserving surgery and definitive breast irradiation for the treatment of ductal carcinoma in situ of the breast.

Authors:  L J Solin; J Kurtz; A Fourquet; R Amalric; A Recht; B A Bornstein; R Kuske; M Taylor; W Barrett; B Fowble; B Haffty; D J Schultz; I T Yeh; B McCormick; M McNeese
Journal:  J Clin Oncol       Date:  1996-03       Impact factor: 44.544

4.  Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience.

Authors:  B Fisher; S Land; E Mamounas; J Dignam; E R Fisher; N Wolmark
Journal:  Semin Oncol       Date:  2001-08       Impact factor: 4.929

5.  Chromosomal alterations in ductal carcinomas in situ and their in situ recurrences.

Authors:  F M Waldman; S DeVries; K L Chew; D H Moore; K Kerlikowske; B M Ljung
Journal:  J Natl Cancer Inst       Date:  2000-02-16       Impact factor: 13.506

6.  Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial.

Authors:  Joan Houghton; W D George; Jack Cuzick; Catherine Duggan; Ian S Fentiman; Margaret Spittle
Journal:  Lancet       Date:  2003-07-12       Impact factor: 79.321

7.  Preoperative evaluation of abnormal mammographic findings to avoid unnecessary breast biopsies.

Authors:  M Morrow; R Schmidt; B Cregger; C Hassett; S Cox
Journal:  Arch Surg       Date:  1994-10

8.  Incidence of and treatment for ductal carcinoma in situ of the breast.

Authors:  V L Ernster; J Barclay; K Kerlikowske; D Grady; C Henderson
Journal:  JAMA       Date:  1996-03-27       Impact factor: 56.272

9.  Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial.

Authors:  Jack Cuzick; Ivana Sestak; Sarah E Pinder; Ian O Ellis; Sharon Forsyth; Nigel J Bundred; John F Forbes; Hugh Bishop; Ian S Fentiman; William D George
Journal:  Lancet Oncol       Date:  2010-12-07       Impact factor: 41.316

10.  Duct carcinoma in situ: predictors of local recurrence and progression in patients treated by surgery alone.

Authors:  P Price; H D Sinnett; B Gusterson; G Walsh; R P A'Hern; J A McKinna
Journal:  Br J Cancer       Date:  1990-06       Impact factor: 7.640

View more
  3 in total

Review 1.  Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential.

Authors:  Lucy M De La Cruz; Nadia F Nocera; Brian J Czerniecki
Journal:  Immunotherapy       Date:  2016-10       Impact factor: 4.196

2.  Wherein the authors attempt to minimize the confusion generated by their study "Breast cancer mortality after a diagnosis of ductal carcinoma in situ" by several commentators who disagree with them and a few who don't: a qualitative study.

Authors:  S A Narod; H Ahmed; V Sopik
Journal:  Curr Oncol       Date:  2017-08-31       Impact factor: 3.677

Review 3.  Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention.

Authors:  Nadia F Nocera; M Catherine Lee; Lucy M De La Cruz; Cinthia Rosemblit; Brian J Czerniecki
Journal:  Front Pharmacol       Date:  2016-10-06       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.